https://wikimd.com/index.php?action=history&feed=atom&title=Lilotomab 2026-04-23T16:49:00Z Revision history for this page on the wiki MediaWiki 1.44.2 https://wikimd.com/index.php?title=Lilotomab&diff=5808186&oldid=prev 2024-05-22T17:04:59Z

<p>CSV import</p> <p><b>New page</b></p><div>[[File:Lutetium-177_satetraxetan.svg|thumb|Lutetium-177_satetraxetan.svg]] &#039;&#039;&#039;Lilotomab&#039;&#039;&#039; is a monoclonal antibody used in the treatment of certain types of [[non-Hodgkin lymphoma]]. It is specifically designed to target the CD37 antigen, which is commonly found on the surface of [[B-cell]] lymphomas.<br /> <br /> ==Mechanism of Action==<br /> Lilotomab works by binding to the CD37 antigen on the surface of B-cells. This binding triggers an immune response that leads to the destruction of the cancerous B-cells. The antibody can also be used in combination with other treatments, such as [[radioimmunotherapy]], to enhance its effectiveness.<br /> <br /> ==Clinical Use==<br /> Lilotomab is primarily used in the treatment of [[non-Hodgkin lymphoma]], particularly in cases where the disease has not responded to other forms of treatment. It is often used in combination with other therapeutic agents to improve patient outcomes.<br /> <br /> ==Development and Approval==<br /> Lilotomab is currently under investigation in clinical trials. It has shown promise in early-phase studies, but further research is needed to confirm its efficacy and safety. The development of Lilotomab is part of ongoing efforts to improve treatment options for patients with [[non-Hodgkin lymphoma]].<br /> <br /> ==Side Effects==<br /> As with other monoclonal antibodies, Lilotomab can cause a range of side effects. Common side effects include infusion reactions, fatigue, and nausea. More serious side effects may include infections and hematologic toxicities. Patients receiving Lilotomab are closely monitored for any adverse reactions.<br /> <br /> ==Research and Future Directions==<br /> Ongoing research is focused on optimizing the use of Lilotomab in combination with other therapies. Studies are also exploring its potential use in other types of [[B-cell]] malignancies. The goal is to enhance the effectiveness of Lilotomab while minimizing side effects.<br /> <br /> ==See Also==<br /> * [[Monoclonal antibody]]<br /> * [[Non-Hodgkin lymphoma]]<br /> * [[B-cell]]<br /> * [[Radioimmunotherapy]]<br /> <br /> ==References==<br /> {{Reflist}}<br /> <br /> ==External Links==<br /> {{Commons category|Lilotomab}}<br /> <br /> [[Category:Monoclonal antibodies]]<br /> [[Category:Non-Hodgkin lymphoma]]<br /> [[Category:Experimental cancer treatments]]<br /> [[Category:Immunotherapy]]<br /> <br /> {{medicine-stub}}</div>

Prab